

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising:
 - (a) a carrier portion;
 - (b) a targeting portion, wherein said targeting portion comprises a targeting peptide; and
 - (c) an immune response triggering portion, wherein said immune response triggering portion triggers a complement mediated hyperacute immune response.
2. The pharmaceutical composition of claim 1, wherein said carrier portion is human serum albumin (HSA).
3. The pharmaceutical composition of claim 1, wherein said targeting peptide comprises asparagine-glycine-arginine (NGR).
4. The pharmaceutical composition of claim 1, where said triggering portion is galactose- α -1,3-galactose.
5. A method for selectively inducing a complement mediated hyperacute immune response to a target tissue comprising treating said tissue with a pharmaceutical composition comprising a carrier portion, a targeting portion and an immune response triggering portion, wherein said targeting portion binds to cells on said tissue.
6. The method of claim 5, wherein said target tissue is the vasculature of a primary or metastatic solid tumor.
7. The method of claim 6, wherein said tumor is a lung, colorectal, bladder, prostate, breast, renal, brain, pancreatic, head, neck or an ovarian tumor.

8. The method of claim 5, wherein said carrier portion is HSA, said targeting portion is NGR and said triggering portion is gal- α -1,3-gal.
9. The method of claim 5, wherein the method of administration of said composition is intravenous.
10. A kit comprising, in a suitable container, a pharmaceutical composition comprising a carrier portion, a targeting portion and an immune response triggering portion.
11. The kit of claim 10, wherein said targeting portion and carrier portion is not an antibody or antibody fragment.
12. The kit of claim 10, wherein said targeting portion selectively binds to tumor vasculature.
13. The kit of claim 10, wherein said targeting portion is a molecule selected from the group consisting of an inhibitor, a ligand, an agonist, an antagonist, and a substrate.
14. The kit of claim 10, wherein said targeting portion comprises a targeting peptide.
15. The kit of claim 14, wherein said targeting peptide comprises asparagine-glycine-arginine (NGR).
16. The kit of claim 10, where said triggering portion triggers a complement mediated hyperacute immune response.
17. The kit of claim 16, where said triggering portion is galactose- α -1,3-galactose.

18. The kit of claim 10, wherein said carrier portion is HSA, said targeting portion is NGR and said triggering portion is galactose- α -1,3-galactose.